Royalty Pharma (NASDAQ:RPRX – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Profitability
This table compares Royalty Pharma and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Royalty Pharma | 32.14% | 30.01% | 14.91% |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
Earnings and Valuation
This table compares Royalty Pharma and Milestone Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Royalty Pharma | $2.38 billion | 15.94 | $770.95 million | $1.45 | 45.47 |
| Milestone Pharmaceuticals | $1.55 million | 63.42 | -$63.06 million | ($0.69) | -1.14 |
Royalty Pharma has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Royalty Pharma has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Royalty Pharma and Milestone Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Royalty Pharma | 0 | 0 | 8 | 0 | 3.00 |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
Royalty Pharma currently has a consensus target price of $61.57, indicating a potential downside of 6.61%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 710.54%. Given Milestone Pharmaceuticals’ higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Royalty Pharma.
Insider and Institutional Ownership
54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Royalty Pharma beats Milestone Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
